

**CORRIGENDUM**

**Corrigendum to ‘A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody’**



[ESMO Open volume 9 issue 6 (2024) 103476]

T. Koyama<sup>1</sup>, N. Kiyota<sup>1,2\*</sup>, S. Boku<sup>3</sup>, Y. Imamura<sup>1</sup>, N. Shibata<sup>3</sup>, H. Satake<sup>3</sup>, K. Tanaka<sup>4</sup>, H. Hayashi<sup>4</sup>, T. Onoe<sup>5</sup>, Y. Asada<sup>6</sup>, T. Yamazaki<sup>7</sup>, T. Nose<sup>1</sup>, S. Ohata<sup>1</sup>, Y. Nagatani<sup>1</sup>, S. Kimbara<sup>1</sup>, Y. Funakoshi<sup>1</sup>, M. Teshima<sup>8</sup>, H. Shinomiya<sup>8</sup> & H. Minami<sup>1,2</sup>

<sup>1</sup>Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe; <sup>2</sup>Cancer Center, Kobe University Hospital, Kobe; <sup>3</sup>Cancer Treatment Center, Kansai Medical University Hospital, Hirakata; <sup>4</sup>Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama; <sup>5</sup>Department of Medical Oncology, Hyogo Cancer Center, Akashi; <sup>6</sup>Department of Head and Neck Surgery, Miyagi Cancer Center, Natori; <sup>7</sup>Department of Head and Neck Oncology, Miyagi Cancer Center, Natori; <sup>8</sup>Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, Kobe, Japan

The authors regret to advise that the data for the number of patients who experienced paronychia (G1/2 shown in Table 3 is incorrect. The number of patients who experienced paronychia (G1/2) was 12, therefore 34% (12/35) is correct.

Paronychia	12 (34%)	1 (2%)	0
------------	----------	--------	---

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.esmoop.2024.103476>

\*Corresponding author: N. Kiyota

E-mail: [nkiyota@med.kobe-u.ac.jp](mailto:nkiyota@med.kobe-u.ac.jp) (N. Kiyota).

2059-7029/© 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).